TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed incurable primary malignant brain tumor that has progressed, recurred, or persisted after initial therapy (must have failed standard therapy).~* Evidence of residual tumor by MRI performed within two weeks prior to study entry~PATIENT CHARACTERISTICS:~Age:~* 6 months to 17 years~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 1,500/mm\^3~* Platelet count greater than 50,000/mm\^3~Hepatic:~* No hepatic failure~* Bilirubin no greater than 2.5 mg/dL~* SGOT/SGPT no greater than 5 times upper limit of normal~Renal:~* Creatinine no greater than 2.5 mg/dL~Cardiovascular:~* No severe heart disease~* No uncontrolled hypertension~Pulmonary:~* No severe lung disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No serious active infections or fever~* No other serious concurrent disease~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulating agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* No concurrent antineoplastic agents~Endocrine therapy:~* Recovered from prior endocrine therapy~* Concurrent corticosteroids for cerebral edema allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy (unless clear radiological evidence of progression) and recovered~Surgery:~* At least 4 weeks since prior surgery (unless clear radiological evidence of progression) and recovered~Other:~* No prior antineoplaston therapy

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Screening of Fibrosing and/or Viral Chronic Hepatopathies in Jail

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Person over 18,~* All new inmates, for less than one month, in Angers jail,~* To have a written informed consent.~Exclusion Criteria:~* No consent obtained from person,~* Detention inferior to one month,~* Person under 18.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of an Educational Program in the Prevention of the Driving Risks in Patients With Neurocognitive Disorders : ACCOMPAGNE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged between 50 and 95 years-old~* hold a driving license,~* drive at least twice a week,~* to have given free and informed consent,~* present a diagnosis of major or minor CNS according to DSM V, whose clinically probable or definite etiology is Alzheimer's or related or vascular disease,~* have a result in the Mini Mental State Examination (MMSE) greater than 18,~* have the ability to speak orally enough or write enough to perform clinical evaluations and workshops, be accompanied by a family member present at least 4 hours a week.~Criteria for inclusion of carers:~* to be a caregiver helping the patient for activities of daily living,~* to have given their free and informed consent,~* have the ability to speak orally and write enough to perform clinical assessments.~Exclusion Criteria:~* have a major psychiatric history, history of alcoholism, anti-depressant~* have sensory problems preventing participation in workshops,~* be affected by any debilitating pathology compromising the health of the patient in the short and medium term,~* be unable to express consent. Criteria for non-inclusion of caregivers: have sensory disturbances preventing participation in workshops.~Recruited patients and caregivers should have been informed and signed a consent.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- educational intervention (Type: EXPERIMENTAL): Patients and caregivers included in the ACCOMPAGNE Education Program group will benefit from seven group workshops spread over three half-days (once a week over 3 consecutive weeks), animated in pairs, each lasting approximately one and a half hours. and using educational pedagogical methods.
- Control group (Type: ACTIVE_COMPARATOR): Patients and caregivers included in the Control group will receive the usual recommendations for driving, issued by their referring doctor in memory consultation during the diagnostic announcement process or during the follow-up of their illness.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oral Vancomycin for Preventing Clostridium Difficile Recurrence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years and older~* Any history of Clostridium difficile infection based on a positive Clostridium difficile stool test performed at a lab affiliated with Rochester Regional Health System or patient report~* A new in-patient admission, with an antibiotic treatment plan for greater than 48 hours~Exclusion Criteria:~* Documented allergy and/or adverse drug reaction to vancomycin~* Pregnant~* Patients who are admitted with a current episode of Clostridium difficile infection~* Patients with total colectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oral vancomycin (Type: EXPERIMENTAL): Oral vancomycin solution 125 mg in 2.5 mL, combined with 2.5 ml Ora-Sweet solution, to total 5 mL.~Taken by mouth once daily for:~1. If the total duration of systemic antibiotics is less than or equal to 14 days, oral vancomycin will be taken for the duration of the systemic antibiotics plus three days.~2. If the total duration of systemic antibiotics is greater than 14 days, oral vancomycin will be taken for the duration of the systemic antibiotics plus seven days.
- Placebo arm (Type: PLACEBO_COMPARATOR): Ora-Sweet 5 mL~Taken by mouth once daily for:~1. If the total duration of systemic antibiotics is less than or equal to 14 days, placebo will be taken for the duration of the systemic antibiotics plus three days.~2. If the total duration of systemic antibiotics is greater than 14 days, placebo will be taken for the duration of the systemic antibiotics plus seven days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Participants had to meet the following criteria to be included:~* Willing and able to read, understand, and sign an informed consent form~* Confirmed diagnosis of WAIHA by enrolling physician~* Must have used medically acceptable contraception~Exclusion Criteria:~Participants who met any of the following criteria were excluded:~* Participant unable or unwilling to comply with the protocol~* Active non-hematologic malignancy or history of non-hematologic malignancy in the 3 years prior to screening (exclusive of non-melanoma skin cancer and cervical cancer in situ)~* Positive for human immunodeficiency virus or hepatitis C antibody~* Positive for hepatitis B surface antigen~* Any exposure to an investigational drug or device within the 30 days prior to screening~* Intravenous immunoglobulin treatment within 30 days of screening~* Plasmapheresis or immunoadsorption within 30 days of screening~* Participant had any current medical condition that, in the opinion of the Investigator, may have compromised their safety or compliance, precluded successful conduct of the study, or interfered with interpretation of the results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: ALXN1830 (Type: EXPERIMENTAL): SYNT001 Dose 1
- Cohort 2: ALXN1830 (Type: EXPERIMENTAL): SYNT001 Dose 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:Histologically confirmed diagnosis of squamous cell carcinoma of the anus. Must be able to provide informed consent. Exclusion Criteria:History of new malignancy since the time of treatment for anal cancer. Non-English speaking.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject must be ≥ 18 years of age at signing of informed consent.~2. Subject must be diagnosed with relapsed or refractory DLBCL (including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma) and scheduled to receive treatment with Yescarta.~3. Female subjects of childbearing potential who are sexually active and male subjects who are sexually active and have female partners of childbearing potential must agree to use a highly effective method of contraception with their partners during exposure to defibrotide and for 30 days after the last dose of defibrotide.~4. Subject must be able to understand and sign written informed consent.~Exclusion Criteria:~1. Subject is currently receiving dialysis or expected to receive dialysis.~2. Subject has used any investigational anticancer agent within 3 weeks prior to the first dose of defibrotide, or is using or plans to use any investigational agent during the study.~3. Subject has previously been treated with CAR-T therapy.~4. Hemodynamic instability requiring vasopressors or uncontrolled hypertension with persistent systolic blood pressure \> 180.~5. Subject has clinically significant active bleeding, history of intracranial bleeding, or is at risk for intracranial bleeding as determined by the Investigator.~6. Subject plans to use any medication that increases the risk of bleeding.~7. Subject is pregnant or lactating and does not agree to stop breastfeeding.~8. Subject has a known history of hypersensitivity to defibrotide or any of the excipients.~9. Subject has primary CNS lymphoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Defibrotide (Type: EXPERIMENTAL): Part 1 (lead-in phase) will evaluate a 2.5 mg/kg/dose regimen before escalating to a 6.25 mg/kg/dose regimen.~After the Safety Assessment Committee establishes the recommended phase 2 dose based on dose-limiting toxicities during Part 1, Part 2 will enroll subjects at the recommended phase 2 dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Validation of the Measurement Accuracy of the Tcore Thermometer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Body temperature \> 34 °C~* Signed consent~* Bladder catheter with temperature sensor~Exclusion Criteria:~* Inflammation of the frontal sinus or the measuring point of the reference measurement (bladder)~* Skin irritation to the adhesive or other materials used~* medication that locally affects the body temperature or the temperature of the reference body site (barbiturates, thyroid preparations, antipsychotics, new vaccines, aspirin, acetaminophen, ibuprofen, or similar)~* Taking antipyretics in the last 120 minutes before measurement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tolvaptan for Advanced or Refractory Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospital admission for ADHF with volume overload as evidenced by ≥ 2 of the following: Elevated JVP, peripheral edema, ascites, pulmonary rales, congestion on chest X-ray, elevated NT-pro-BNP \> 2000 pg/ml~* Inadequate clinical response indicated by body weight loss \< 1.0 kg/day over 48 hours despite adequate doses of IV loop diuretic (at least 40 mg furosemide daily) and fluid restriction 2 L/24 hours.~* ≥1 of the following over the preceding 48 hours: Potential need for inotropic support to improve urine output, and/or renal insufficiency (estimated glomerular filtration rate \<45 mL/min/1.73 m2)~* Serum sodium ≤134 mmol/L~* ≥18 years-old~Exclusion Criteria:~* Cardiac surgery within 60 days of enrollment~* Planned cardiac mechanical support or transplant; subjects with previously implanted ventricular assist device (VAD) will not be excluded~* Need for intravenous pressor support for symptomatic hypotension~* Biventricular pacemaker placement within the last 60 days~* Hemofiltration or dialysis~* Known cirrhosis~* Supine systolic arterial blood pressure less than 85 mmHg~* Refusal or inability to sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tolvaptan (Type: EXPERIMENTAL): Tolvaptan 15-60 mg, once daily for 4 days or until hospital discharge
- Standard of care diuretic therapy (Type: ACTIVE_COMPARATOR): Usual standard of care diuretic therapy for patients with acute decompensated heart failure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Using Lay Health Advisors to Improve Hypertension Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 2 outpatient blood pressures with systolic \>140 or diastolic \>90 mm Hg in last 6 months. Separate occurrences at least 1 day apart~* Age 18-59 years~* Non-diabetic~* Preserved kidney function (glomerular filtration rate \>60 ml/min)~* English speaking~Exclusion Criteria:~* Mentally incompetent~* Pregnant~* Terminal illness~* Active substance abuse~* Documented coronary, peripheral arterial, or cerebrovascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Lay Health Advisors (Type: EXPERIMENTAL): Intervention patients will meet monthly in small groups with a trained Lay Health Advisor.
- Usual Care (Type: NO_INTERVENTION): Control patients will receive usual care from their doctors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ages 7-70 years old~* Renal biopsy, diagnostic for IgA nephropathy~* Must be able to take oral medication~Exclusion Criteria:~* Clinical and histologic evidence of systemic lupus erythematosus~* Well-documented history of Henoch-Schonlein purpura.~* Clinical evidence of cirrhosis or chronic liver disease~* Abnormal laboratory values at the time of study entry~* Estimated GFR outside of protocol defined limits~* History of significant gastrointestinal disorder~* Active systemic infection or history of serious infection within one month of entry or known infection with HIV, hepatitis B, or hepatitis C.~* Other major organ system disease or malignancy~* Current or prior treatment with MMF or azathioprine

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Mycophenolate Mofetil (MMF) (Type: ACTIVE_COMPARATOR): Dose is based on body size (between 25mg/kg/day and 36mg/kg/day with a maximum dose 1gm BID; initial dose to be used in the first 2 weeks of therapy will be approximately 1/2-2/3 of the full dose). Route of administration is oral. Frequency is daily. MMF will be administered up to 12 months.
- MMF Placebo (Type: PLACEBO_COMPARATOR): Subjects receive MMF placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* COVID-19 positive patients~* Treated at the Health Institute of the State of Mexico (ISEM).~* With risk factors to get complicated: age more than 60 years old, diabetes mellitus or obesity grade II or more.~Exclusion Criteria:~* Patients who have inherent contraindications to each drug.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nitazoxanide + hydroxychloroquine (Type: EXPERIMENTAL): Hydroxychloroquine 400 mg PO every 12 hours for two days and then 200 mg PO every 12 hours for four days + Nitazoxanide 500 mg PO every 6 hours for six days
- Hydroxychloroquine (Type: ACTIVE_COMPARATOR): Hydroxychloroquine 200 mg PO every 12 hours for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must have disease progression after treatment with available therapies that are known to confer clinical benefit or must be intolerant to or ineligible for standard treatment.~* Histologically confirmed advanced solid tumors (protocol-defined select solid tumors) with measurable lesions per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) that are considered nonamenable to surgery or other curative treatments or procedures.~* ECOG performance status score of 0 or 1.~* Life expectancy \> 12 weeks.~* Willingness to avoid pregnancy or fathering children.~Exclusion Criteria:~Exclusion Criteria:~* Laboratory values outside the Protocol-defined ranges.~* Clinically significant cardiac disease.~* History or presence of an ECG that, in the investigator's opinion, is clinically meaningful.~* Untreated brain or central nervous system (CNS) metastases or brain or CNS metastases that have progressed (eg, evidence of new or enlarging brain metastasis or new neurological symptoms attributable to brain or CNS metastases).~* Known additional malignancy that is progressing or requires active treatment.~* Has not recovered to ≤ Grade 1 or baseline from toxic effects of prior therapy (including prior IO) and/or complications from prior surgical intervention before starting study treatment.~* Prior receipt of an anti-PD-L1 therapy.~* Treatment with anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.~* A 28-day washout for systemic antibiotics is required.~* Probiotic usage while on study and during screening is prohibited.~* Active infection requiring systemic therapy.~* Known history of HIV~* Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Participants with select solid tumors who are immunotherapy treatment-naive
- Cohort 2 (Type: EXPERIMENTAL): Participants with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) tumors who are immunotherapy treatment-naïve.
- Cohort 3 (Type: EXPERIMENTAL): Participants with progression of any solid tumor treated with an approved anti-PD-1 monoclonal antibody therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues